William Blair Has Pessimistic Outlook of AXSM Q1 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at William Blair reduced their Q1 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a report issued on Tuesday, April 1st. William Blair analyst M. Minter now anticipates that the company will post earnings of ($1.49) per share for the quarter, down from their prior forecast of ($1.46). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.31) EPS, Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($4.36) EPS, Q1 2026 earnings at ($0.44) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at $0.47 EPS, Q4 2026 earnings at $1.13 EPS, FY2026 earnings at $1.10 EPS, FY2027 earnings at $12.30 EPS, FY2028 earnings at $25.02 EPS and FY2029 earnings at $38.11 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million.

A number of other equities analysts have also commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday, April 1st. Royal Bank of Canada lifted their price target on Axsome Therapeutics from $143.00 to $192.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 19th. Wells Fargo & Company increased their price objective on Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Leerink Partners boosted their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, February 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Axsome Therapeutics in a report on Thursday. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $167.64.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $98.86 on Friday. The firm has a market capitalization of $4.82 billion, a PE ratio of -16.50 and a beta of 0.88. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $139.13. The firm’s fifty day simple moving average is $120.62 and its 200 day simple moving average is $101.75.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Raiffeisen Bank International AG acquired a new stake in Axsome Therapeutics during the 4th quarter valued at $51,000. Assetmark Inc. bought a new stake in shares of Axsome Therapeutics during the fourth quarter worth $52,000. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at $64,000. Aquatic Capital Management LLC bought a new position in shares of Axsome Therapeutics in the fourth quarter valued at about $76,000. Finally, GF Fund Management CO. LTD. acquired a new position in Axsome Therapeutics during the 4th quarter worth about $86,000. Institutional investors own 81.49% of the company’s stock.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 22.40% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.